MIRATI THERAPEUTICS, INC.

(MRTX)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
71.96 USD   +1.10%
06/24MIRATI THERAPEUTICS, INC.(NASDAQGS : MRTX) dropped from Russell 2500 Growth Index
CI
06/24MIRATI THERAPEUTICS, INC.(NASDAQGS : MRTX) dropped from Russell Midcap Growth Index
CI
06/24MIRATI THERAPEUTICS, INC.(NASDAQGS : MRTX) dropped from Russell 3000E Growth Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mirati lung cancer data disappoint, shares fall 21%

05/26/2022 | 06:59pm EDT

May 26 (Reuters) - An experimental Mirati Therapeutics Inc drug that targets a specific genetic mutation shrank tumors in 44% of advanced lung cancer patients in clinical trials, but also caused serious side effects in 43% of them, the company said on Thursday.

Details from studies of the drug, adagrasib, were released ahead of the early June annual meeting of the American Society of Clinical Oncology (ASCO), sending shares of Mirati down more than 21% in after hours trading.

The oral drug is designed to target a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common type of lung cancer.

The first drug in this class, Amgen Inc's Lumakras, was approved by the U.S. Food and Drug Administration last year. Amgen in April reported data showing that its drug shrank tumors in 41% of advanced NSCLC patients.

The drugs are part of a growing trend of medicines that target gene mutations driving cancer regardless of which organ the disease originated.

The FDA is slated to make an approval decision on Mirati's drug by mid-December.

Mirati on Thursday said updated data from the Phase II study under review at the FDA shows that 43% of trial participants experienced serious treatment-related side effects, including increased levels of liver enzymes and anemia.

Two treatment-related deaths were reported and 7% of trial participants discontinued the treatment.

Mirati at the ASCO meeting is scheduled to present additional data on how effective adagrasib is at treating NSCLC that has spread to the brain.

The California-based company is also testing the drug as an initial treatment for NSCLC, both alone and in combination with Merck & Co's immunotherapy Keytruda.

Shares of Mirati, which closed at $58.76 in regular trading, were down $12.46, or 21.3%, at $46 after hours. (Reporting By Deena Beasley; Editing by Bill Berkrot and Richard Pullin)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. 0.48% 246.73 Delayed Quote.9.15%
MIRATI THERAPEUTICS, INC. 1.10% 71.96 Delayed Quote.-51.48%
All news about MIRATI THERAPEUTICS, INC.
06/24MIRATI THERAPEUTICS, INC.(NASDAQGS : MRTX) dropped from Russell 2500 Growth Index
CI
06/24MIRATI THERAPEUTICS, INC.(NASDAQGS : MRTX) dropped from Russell Midcap Growth Index
CI
06/24MIRATI THERAPEUTICS, INC.(NASDAQGS : MRTX) dropped from Russell 3000E Growth Index
CI
06/24MIRATI THERAPEUTICS, INC.(NASDAQGS : MRTX) dropped from Russell Small Cap Comp Growth Inde..
CI
06/24MIRATI THERAPEUTICS, INC.(NASDAQGS : MRTX) dropped from Russell 1000 Growth Index
CI
06/24MIRATI THERAPEUTICS, INC.(NASDAQGS : MRTX) dropped from Russell 3000 Growth Index
CI
06/16TRANSCRIPT : Mirati Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Health..
CI
06/09Oppenheimer Adjusts Mirati Therapeutics Price Target to $85 From $105, Maintains Perfor..
MT
06/09TRANSCRIPT : Mirati Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Confer..
CI
06/07SECTOR UPDATE : Health Care Stocks Rebound Tuesday
MT
More news
Analyst Recommendations on MIRATI THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 8,21 M - -
Net income 2022 -801 M - -
Net cash 2022 785 M - -
P/E ratio 2022 -4,99x
Yield 2022 -
Capitalization 3 952 M 3 952 M -
EV / Sales 2022 386x
EV / Sales 2023 22,8x
Nbr of Employees -
Free-Float 94,0%
Chart MIRATI THERAPEUTICS, INC.
Duration : Period :
Mirati Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRATI THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 71,96 $
Average target price 122,00 $
Spread / Average Target 69,5%
EPS Revisions
Managers and Directors
David D. Meek Chief Executive Officer & Director
Charles M. Baum President, Director & Head-Research & Development
Laurie D. Stelzer Chief Financial & Accounting Officer
Faheem Hasnain Chairman
James G. Christensen Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
MIRATI THERAPEUTICS, INC.-51.48%3 952
GILEAD SCIENCES, INC.-14.12%78 219
VERTEX PHARMACEUTICALS30.84%73 484
REGENERON PHARMACEUTICALS, INC.-5.72%64 152
WUXI APPTEC CO., LTD.-4.30%47 357
BIONTECH SE-38.91%38 276